Cellectar Biosciences Inc (CLRB)
3.11
+0.05
(+1.63%)
USD |
NASDAQ |
May 24, 16:00
3.095
-0.02
(-0.48%)
After-Hours: 20:00
Cellectar Biosciences Cash from Financing (Quarterly): 43.85M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 43.85M |
December 31, 2023 | 0.441M |
September 30, 2023 | 22.50M |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 9.611M |
September 30, 2022 | 0.00 |
June 30, 2022 | 0.00 |
March 31, 2022 | 0.00 |
December 31, 2021 | -0.00 |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.0349M |
March 31, 2021 | 1.214M |
December 31, 2020 | 42.21M |
September 30, 2020 | -0.1062M |
June 30, 2020 | 18.44M |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | -0.0006M |
June 30, 2019 | 9.024M |
March 31, 2019 | -0.0008M |
December 31, 2018 | -0.0008M |
September 30, 2018 | 15.12M |
June 30, 2018 | -0.0939M |
March 31, 2018 | -0.0007M |
Date | Value |
---|---|
December 31, 2017 | 7.170M |
September 30, 2017 | -0.0814M |
June 30, 2017 | -0.0075M |
March 31, 2017 | 2.848M |
December 31, 2016 | 8.214M |
September 30, 2016 | -0.0616M |
June 30, 2016 | 7.920M |
March 31, 2016 | -0.1312M |
December 31, 2015 | 2.898M |
September 30, 2015 | -0.1896M |
June 30, 2015 | -0.0009M |
March 31, 2015 | -0.0012M |
December 31, 2014 | 0.00 |
September 30, 2014 | 12.05M |
June 30, 2014 | -0.1742M |
March 31, 2014 | 3.999M |
December 31, 2013 | -0.0006M |
September 30, 2013 | -0.0006M |
June 30, 2013 | -0.0006M |
March 31, 2013 | 5.045M |
December 31, 2012 | 2.834M |
September 30, 2012 | 0.1502M |
June 30, 2012 | 4.870M |
March 31, 2012 | -0.0005M |
December 31, 2011 | 5.457M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1062M
Minimum
Sep 2020
43.85M
Maximum
Mar 2024
7.361M
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
Perspective Therapeutics Inc | 166.33M |
Eli Lilly and Co | -311.30M |
Actinium Pharmaceuticals Inc | 14.77M |
Bristol-Myers Squibb Co | 14.64B |
Altimmune Inc | -0.261M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -13.36M |
Cash from Investing (Quarterly) | -0.0216M |
Free Cash Flow | -39.44M |
Free Cash Flow Per Share (Quarterly) | -0.456 |
Free Cash Flow Yield | -75.75% |